SCHEMBL30775285

SCHEMBL30775285

CN(C)c1ccc(-c2cccc3c2CNC3=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.57
PIM1 P11309 3/20 0.50
ROCK1 Q13464 3/20 0.50
CLK4 Q9HAZ1 3/20 0.50
ROCK2 O75116 3/20 0.50
MAP4K4 O95819 2/20 0.50
LCK P06239 2/20 0.50
RET P07949 2/20 0.50
RPS6KB1 P23443 2/20 0.50
BLK P51451 2/20 0.50
STK3 Q13188 2/20 0.50
NTRK3 Q16288 2/20 0.50
TAOK1 Q7L7X3 2/20 0.50
HIPK4 Q8NE63 2/20 0.50
AURKB Q96GD4 2/20 0.50
MKNK2 Q9HBH9 2/20 0.50
MAP4K5 Q9Y4K4 2/20 0.50
CDK5 Q00535 2/20 0.50
DYRK1A Q13627 2/20 0.50
CSNK1A1 P48729 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30331758 0.80 PARP10 (0.69) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL19608227 0.79 PIK3CD (0.64) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL1333209 0.79 KDR (0.57) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL28223904 0.79 PIK3CD (0.64) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL28860691 0.78 KDR (0.54) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL1333899 0.78 KDR (0.65) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL28224571 0.78 KDR (0.62) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL30543353 0.78 KDR (0.62) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL30775345 0.78 PIK3CD (0.49) KDRPIM1ROCK1CLK4ROCK2
SCHEMBL1333737 0.77 KDR (0.53) KDRPIM1ROCK1CLK4ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR KDR 4622/4885PIM1 4064/4885ROCK1 1533/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR KDR 4622/4885PIM1 4064/4885ROCK1 1533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.